Quantum computing has rapidly advanced in recent years due to substantial development in both hardware and algorithms. These advances are carrying quantum computers closer to their impending commercial utility. Drug discovery is a promising area of application that will find a number of uses for these new machines. As a prominent example, quantum simulation will enable faster and more accurate characterizations of molecular systems than existing quantum chemistry methods. Furthermore, algorithmic developments in quantum machine learning offer interesting alternatives to classical machine learning techniques, which may also be useful for the biochemical efforts involved in early phases of drug discovery. Meanwhile, quantum hardware is scaling up rapidly into a regime where an exact simulation is difficult even using the world’s largest supercomputers. We review how these recent advances can shift the paradigm with which one thinks about drug discovery, focusing on both the promises and caveats associated with each development. In particular, we highlight how hybrid quantum-classical approaches to quantum simulation and quantum machine learning could yield substantial progress using noisy-intermediate scale quantum devices, whereas fault-tolerant, error-corrected quantum computers are still in their development phase.
Quantum computing has rapidly advanced in recent years due to substantial development in both hardware and algorithms. These advances are carrying quantum computers closer to their impending commercial utility. Drug discovery is a promising area of application that will find a number of uses for these new machines. As a prominent example, quantum simulation will enable faster and more accurate characterizations of molecular systems than existing quantum chemistry methods. Furthermore, algorithmic developments in quantum machine learning offer interesting alternatives to classical machine learning techniques, which may also be useful for the biochemical efforts involved in early phases of drug discovery. Meanwhile, quantum hardware is scaling up rapidly into a regime where an exact simulation is difficult even using the world’s largest supercomputers. We review how these recent advances can shift the paradigm with which one thinks about drug discovery, focusing on both the promises and caveats associated with each development. In particular, we highlight how hybrid quantum-classical approaches to quantum simulation and quantum machine learning could yield substantial progress using noisy-intermediate scale quantum devices, whereas fault-tolerant, error-corrected quantum computers are still in their development phase.
Drug discovery and development is a time-consuming and cost-intensive process. Computer-aided drug design can speed up the timeline and reduce costs by decreasing the number of necessary biochemical experiments. The number of studies using quantum computing to solve problems in drug development has been increasing in recent years. In this review, we briefly introduce the main steps in drug discovery and development and how computers help to find potential drug candidates. Recent studies of quantum computing in drug development based on the structure of target proteins are listed chronologically. They include protein structure prediction, molecular docking, quantum simulation, and quantitative structure-activity relationship (QSAR) models. Current quantum devices are still susceptible to noise and error but are well suited for hybrid quantum-classical algorithms. The quantum advantage is demonstrated on hybrid systems and quantum-inspired devices such as quantum annealers. We hope to see more applications of quantum computing in the field of drug discovery and development.
Quantum computing has emerged as a potential catalyst for addressing computational bottlenecks that increasingly constrain biotechnologies, including drug discovery, structural biology, and precision medicine. As biological datasets grow in scale and complexity, classical high-performance computing struggles to efficiently model molecular interactions and high-dimensional biological systems. Recent advances in hybrid quantum-classical algorithms and quantum-enhanced machine learning have enabled early proof-of-concept applications on noisy intermediate-scale quantum (NISQ) devices, offering new strategies for molecular simulation, pattern recognition, and optimization. In this opinion article, we critically assess where quantum computing may deliver realistic near-term value for biomedicine, emphasize hybrid workflows as the most viable path forward, and outline how quantum technologies could complement, not replace, existing computational paradigms as the field progresses toward fault-tolerant systems.
INTRODUCTION: Quantum computing represents a transformative advancement in computational science, with applications in drug discovery, molecular interaction simulation, drug-target binding optimization, and the analysis of complex biological data at unprecedented speeds and accuracy. Quantum computing emerges as a powerful tool to accelerate the development of new therapeutics, drug design, and the simulation of complex chemical interactions, including personalized medicine strategies. The objective of this study is to explore the potential of quantum computing in drug discovery and development, highlighting its ability to reduce time and costs while accelerating the identification of promising drug candidates. METHODS: Quantum computing algorithms, such as Grover's algorithm and the Variational Quantum Eigensolver (VQE), are utilized to simulate molecular interactions of drugs and optimize drug design. In case studies, such as IBM's use of VQE for molecular simulations, these technologies demonstrate their effectiveness. RESULTS: Quantum computing has shown promise in addressing several technological barriers, such as lengthy development timelines and high costs. Additionally, demonstrated success in molecular simulations and solving challenges during the drug development process. However, challenges related to error rates, qubit coherence, and regulatory compliance remain. DISCUSSION: This study examines the applications of quantum computing in drug discovery, highlighting key techniques such as quantum simulation, quantum machine learning, and optimization algorithms. Quantum computing is crucial for interdisciplinary collaboration among quantum physicists, computational chemists, biologists, and pharmaceutical professionals, as it is essential to overcoming these obstacles and realizing the full potential of quantum technologies in medicine. CONCLUSION: Quantum computing holds great potential in drug discovery and development, offering accelerated, more accurate, and lower-cost research avenues, particularly in complex areas such as protein folding prediction and personalized medicine. This new paradigm has tremendous potential for guiding the future of pharmaceutical development and patient-focused medicine.
Quantum chemistry plays a crucial role in advancing fundamental understanding of chemical processes and driving innovation in energy, medicine, and materials science. Recent progress in quantum computing has opened new possibilities for molecular simulations that are beyond the practical limits of classical approaches. Academic studies have demonstrated hybrid Density Functional Theory (DFT) and Variational Quantum Eigensolver (VQE) benchmarks on small transition-metal systems, such as iron porphyrin and heme analogues, using current noisy intermediate-scale quantum (NISQ) hardware. Although full-scale simulations of complex biological systems such as the complete Cytochrome P450 (CYP450) active site remain a long-term goal due to limitations in qubit numbers, coherence times, and error correction, the underlying methodologies are now well established. At present, quantum chemistry applications in drug discovery remain largely experimental, and widespread practical medical impact is expected to require further technological advances over the next 5–10 years. Nevertheless, quantum software and algorithm development for chemical applications is progressing rapidly. This perspective summarizes recent advances in quantum computing algorithms, hardware, and software relevant to chemistry, and critically discusses the remaining challenges and opportunities for applying quantum computing to chemical problems, with particular emphasis on drug discovery and development.
Drug development remains a complex, time-intensive, and costly process, with high failure rates in clinical trials. The advent of quantum computing presents promising opportunities to transform pharmaceutical research and development through enhanced molecular simulations and structure-based drug design. Quantum computing uses quantum mechanical phenomena like superposition and entanglement to process complex molecular interactions more efficiently than classical computers. The integration of quantum computing with machine learning algorithms has enabled more accurate predictions of drug-target interactions and improved virtual screening of compound libraries. Applications include structure-based drug design, molecular docking, lead optimization, and drug repurposing. Notable progress has been made through collaborations between pharmaceutical companies and quantum computing firms, demonstrating practical implementations in drug discovery workflows. However, several challenges persist, including hardware limitations, algorithmic maturity, skilled workforce gaps, and regulatory considerations. The combination of quantum computing with classical computing and machine learning approaches offers a hybrid framework that maximizes the strengths of each technology. As quantum computing technology advances, it is positioned to significantly impact pharmaceutical research and development, potentially reducing development timelines and improving success rates in drug discovery. This review explains the principles, current applications, integration, and limitations of quantum computing in drug development
Quantum AI, the integration of quantum computing and artificial intelligence, is revolutionizing drug design by addressing the limitations of traditional pharmaceutical development. This review explores its transformative potential in enhancing molecular simulations, structure-based, target-based, and ligand-based drug discovery, and personalized medicine. Quantum computing leverages principles like superposition, entanglement, and interference to perform complex calculations exponentially faster than classical systems, enabling precise modeling of molecular interactions. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Phase Estimation (QPE) outperform classical methods like Density Functional Theory (DFT) in accuracy and efficiency, facilitating the identification of promising drug candidates and optimizing their pharmacokinetic properties. Quantum AI also enhances personalized medicine by analyzing vast genomic datasets to tailor treatments, improving efficacy and minimizing adverse effects. Despite challenges, including noisy intermediate-scale quantum (NISQ) device limitations and the need for advanced error correction, ongoing research and interdisciplinary collaboration are driving progress. Quantum AI promises to reduce development costs, accelerate drug discovery, and democratize access to life-saving medications. By enabling simulation-based discovery and expanding drug-candidate libraries to include peptides and antibodies, it paves the way for breakthroughs in treating complex diseases. This review underscores the need for continued investment in quantum technology to fully harness its potential, positioning the pharmaceutical industry for a future where drug development is faster, more precise, and patient-centric, ultimately improving global healthcare outcomes.